Your browser doesn't support javascript.
Rebound Phenomenon after Nirmatrelvir/Ritonavir Treatment of Coronavirus Disease-2019 in High-Risk Persons.
Ranganath, Nischal; O'Horo, John C; Challener, Douglas W; Tulledge-Scheitel, Sidna M; Pike, Marsha L; Michael O'Brien, R; Razonable, Raymund R; Shah, Aditya.
  • Ranganath N; Division of Public Health, Infectious Diseases and Occupational Medicine, Mayo Clinic, Rochester, MN USA.
  • O'Horo JC; Division of Public Health, Infectious Diseases and Occupational Medicine, Mayo Clinic, Rochester, MN USA.
  • Challener DW; Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, USA.
  • Tulledge-Scheitel SM; Division of Public Health, Infectious Diseases and Occupational Medicine, Mayo Clinic, Rochester, MN USA.
  • Pike ML; Division of Community Internal Medicine, Mayo Clinic, Rochester, MN, USA.
  • Michael O'Brien R; Department of Nursing, Mayo Clinic, Rochester, MN, USA.
  • Razonable RR; Department of Pharmacy, Mayo Clinic, Rochester, MN, USA.
  • Shah A; Division of Public Health, Infectious Diseases and Occupational Medicine, Mayo Clinic, Rochester, MN USA.
Clin Infect Dis ; 2022 Jun 14.
Article in English | MEDLINE | ID: covidwho-2234739
ABSTRACT
In a cohort of 483 high-risk patients treated with nirmatrelvir/ritonavir for coronavirus disease-2019, two patients (0.4%) required hospitalization by day 30. Four patients (0.8%) experienced rebound of symptoms, which were generally mild, at median of 9 days after treatment, and all resolved without additional COVID-19-directed therapy.

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Observational study / Prognostic study Language: English Journal subject: Communicable Diseases Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Observational study / Prognostic study Language: English Journal subject: Communicable Diseases Year: 2022 Document Type: Article